Results 11 to 20 of about 5,130,717 (259)

Biological synthesis of ursodeoxycholic acid

Frontiers in Microbiology, 2023
Ursodeoxycholic acid (UDCA) is a fundamental treatment drug for numerous hepatobiliary diseases that also has adjuvant therapeutic effects on certain cancers and neurological diseases. Chemical UDCA synthesis is environmentally unfriendly with low yields.
Peng Song, Peng Song, Xue Zhang, Wei Feng, Wei Xu, Chaoyun Wu, Shaoqing Xie, Sisi Yu, Rongzhao Fu   +8 more
doaj   +2 more sources

Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials

Lipids in Health and Disease, 2019
Objective The aim of this meta-analysis of randomized placebo-controlled trials was to examine whether ursodeoxycholic acid treatment is an effective lipid-lowering agent.
Luis E. Simental-Mendía, Mario Simental-Mendía, Adriana Sánchez-García, Maciej Banach, Maria-Corina Serban, Arrigo F. G. Cicero, Amirhossein Sahebkar   +6 more
doaj   +2 more sources

Gut microbiota-derived ursodeoxycholic acid alleviates low birth weight-induced colonic inflammation by enhancing M2 macrophage polarization

Microbiome, 2023
Background Low birth weight (LBW) is associated with intestinal inflammation and dysbiosis after birth. However, the underlying mechanism remains largely unknown.
Y. Pi, Yujun Wu, Xiangyu Zhang, D. Lu, Dandan Han, Jiangchao Zhao, Xiaojiao Zheng, Shiyi Zhang, Hao Ye, S. Lian, Yu Bai, Zhenyu Wang, S. Tao, Dongjiao Ni, Xinhua Zou, W. Jia, Guolong Zhang, Defa Li, Junjun Wang   +18 more
semanticscholar   +1 more source

Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation

Nature Communications, 2022
TGF-β is essential for inducing systemic tumor immunosuppression; thus, blocking TGF-β can greatly enhance antitumor immunity. However, there are still no effective TGF-β inhibitors in clinical use.
Yingying Shen, Chaojie Lu, Zhengbo Song, Chen Qiao, Jiaoli Wang, Jinbiao Chen, Chengyan Zhang, Xianchang Zeng, Zeyu Ma, Tao Chen, Xu Li, Aifu Lin, Jufeng Guo, Jianli Wang, Zhijian Cai   +14 more
semanticscholar   +1 more source

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients

Pharmaceuticals, 2022
Non-alcoholic fatty liver disease (NAFLD) is related to metabolic syndrome via insulin resistance, where preventing disease progression is crucial in the management process.
S. Elhini, E. Wahsh, A. Elberry, Nadia F El Ameen, Ahmed Abdelfadil Saedii, S. Refaie, Asmaa A. Elsayed, H. Rabea   +7 more
semanticscholar   +1 more source

Beneficial effect of ursodeoxycholic acid in patients with acyl‐CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

Hepatology, 2022
A variant (p.Arg225Trp) of peroxisomal acyl‐CoA oxidase 2 (ACOX2), involved in bile acid (BA) side‐chain shortening, has been associated with unexplained persistent hypertransaminasemia and accumulation of C27‐BAs, mainly 3α,7α,12α‐trihydroxy‐5β ...
M. Alonso-Peña, Ricardo Espinosa-Escudero, E. Herráez, O. Briz, M. Cagigal, J. González-Santiago, A. Ortega-Alonso, C. Fernández-Rodríguez, L. Bujanda, Marta Calvo Sanchez, Delia D´Avola, M. Londoño, M. Diago, J. Fernández-Checa, C. Garcia-Ruiz, R. Andrade, F. Lammert, J. Prieto, J. Crespo, J. Juamperez, Á. Díaz-González, M. Monte, J. Marin   +22 more
semanticscholar   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis

Cell Death Discovery, 2021
The Hippo/YAP pathway plays an important role in the development of cancers. Previous studies have reported that bile acids can activate YAP (Yes Associated Protein) to promote tumorigenesis and tumor progression.
Huan Zhang, Huanji Xu, Chenliang Zhang, Qiu-lin Tang, F. Bi   +4 more
semanticscholar   +1 more source

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review

Frontiers in Pharmacology, 2021
Introduction: Treatment is generally not available for drug-induced liver injury (DILI) patients except in some specific circumstances. The management of DILI is based on the withdrawal of the responsible drug and monitoring the patients and only a few ...
M. Robles-Díaz, L. Nežić, V. vujić-Aleksić, E. Björnsson   +3 more
semanticscholar   +1 more source